Stage II in the development of Eph/ephrin based tumor targeting reagents: Optimisation of drug efficacy and delivery [ 2004 - 2005 ]

Research Grant

Researchers: A/Pr Martin Lackmann (Principal investigator) ,  E/Pr Andrew Boyd ,  Herbert Treutlein ,  Prof Andrew Scott

Brief description In the final stage of cancer, including melanoma, tumor cells gain the ability to spread, a process called metastasis. Altered communication between cancer and normal cells is one of the causes of this invasive characteristic. We have started the development of novel agents that target and modulate proteins on the cell surface that control these properties and are found in metastatic tumors. We propose to refine the targeting and killing properties of these agents for early clinical testing.

Funding Amount $AUD 204,125.00

Funding Scheme NHMRC Development Grants

Notes Development Grant